Patent ID: 7807688
Filing Date: 2010-10-05
Classification: A61P,C07D

Abstract:
1. A method for the treatment of a disease induced by extraordinary secretion of Corticotropin Releasing Factor, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) wherein X and Y each independently, is carbon or nitrogen and both are not nitrogens at the same time; W is carbon or nitrogen; U and Z each independently, is CR R (i) hydrogen, (ii) C1-8 alkyl, (iii) C2-8 alkenyl, (iv) C2-8 alkynyl, (v) halogen atom, (vi) CF (vii) cyano, (viii) nitro, (ix) NR (x) OR (xi) SH, (xii) S(O) (xiii) COR (xiv) COOR (xv) CONR (xvi) C3-10 mono- or bi-carbocyclic ring, (xvii) 3-10 membered mono- or bi-heterocyclic ring containing 1-4 of nitrogen(s), 1-2 of oxygen(s) and/or 1-2 of sulfur(s) or (xviii) C1-4 alkyl substituted by 1-2 of substitutes selected from halogen atom, CF R (i) hydrogen, (ii) C1-4 alkyl, (iii) C2-4 alkenyl, (iv) C2-4 alkynyl, (v) C3-10 mono- or bi-carbocyclic ring, (vi) 3-10 membered mono- or bi-heterocyclic ring containing 1-4 of nitrogen(s), 1-2 of oxygen(s) and/or 1-2 of sulfur(s) or (vii) C1-4 alkyl substituted by C3-10 mono- or bi-carbocyclic ring or 3-10 membered mono- or bi-heterocyclic ring containing 1-4 of nitrogen(s), 1-2 of oxygen(s) and/or 1-2 of sulfur(s), is C4-6 carbocyclic ring or 4-6 membered heterocyclic ring containing at least one of nitrogen, oxygen and sulfur and these rings are unsubstituted or substituted by 1-3 of substitutes selected from C1-4 alkyl, C1-4 alkoxy, halogen atom and CF 3 , C1-4 alkyl, C1-4 alkoxy, R (i) C1-8 alkyl which is unsubstituted or substituted by 1-5 of R (ii) C2-8 alkenyl which is unsubstituted or substituted by 1-5 of R (iii) C2-8 alkynyl which is unsubstituted or substituted by 1-5 of R (iv) NR (v) OR (vi) SH, (vii) S(O) (viii) COR (ix) COOR (x) CONR (xi) NR (xii) NR (xiii) NR (xiv) C3-15 mono- or bi-carbocyclic ring which is unsubstituted or substituted by 1-5 of R (xv) 3-15 membered mono- or bi-heterocyclic ring containing 1-4 of nitrogen(s), 1-2 of oxygen(s) and/or 1-2 of sulfur(s) which is unsubstituted or substituted by 1-5 of R R R R R R R R R (ii) 5-10 membered mono- or bi-heterocyclic ring containing 1-4 of nitrogen(s), 1-2 of oxygen(s) and/or 1-2 of sulfur(s) substituted by 1-5 of R R (b) C2-8 alkenyl, (c) C2-8 alkynyl, (d) halogen atom, (e) CF (f) OCF (g) cyano, (h) nitro, (j) NR (k) OR (l) SH, (m) S(O) (n) COR (o) COOR (p) CONR (q) NR (r) NR (s) NR (t) C3-10 mono- or bi-carbocyclic ring, (u) 3-10 membered mono- or bi-heterocyclic ring containing 1-4 of nitrogen(s), 1-2 of oxygen(s) and/or 1-2 of sulfur(s) (v) C1-4 alkyl substituted by 1-2 of substitutes selected from halogen atom, CF with the proviso that (1) when each of X and W is carbon, each of Y and Z is nitrogen, U is —CR a pharmaceutically acceptable salt thereof or a hydrate thereof as active ingredient, wherein the disease is selected from the group consisting of depression, anxiety, anxiety-related disorders, eating disorder, obesity, irritable bowel syndrome, ischemic neuron injury, ischemic disease, drug addiction or alcohol dependence syndrome, emotional disorder, bipolar disorder, post-traumatic stress disorder, diarrhea, constipation, and stress-induced sleep disorder.